Fifty Residues
Peptide science in plain words, with the sources attached.
A guide for anyone who has met the word in the news, in the gym or at the bench and wants the plain version. What a peptide is and how it differs from a protein or a pill. How one is built, purified and checked. A century of history from insulin to the GLP-1 medicines. Where peptides are studied, the properties researchers value, how they are stored, and how to read the certificate that arrives with a vial.
Written and checked by the editors. No products, no amounts, no advice. Fourteen sources, every one linked.
Main peak, share of total peak area98.6%
The word peptide turns up in the news, in the gym and in the laboratory, and it rarely means the same thing in all three places. This long read sets out what the science actually says: what peptides are, how they are built and checked, the century of work behind them, where they are studied today, and the properties that make researchers keep coming back to them. It makes no claims about effects in people and gives no amounts, because that is not what an explainer is for. Every factual claim carries a numbered source, and every source is linked at the end.
1
A peptide is a short chain of amino acids. Amino acids are the twenty or so standard building blocks of all proteins, and when two of them join, the carboxyl group of one links to the amino group of the next through an amide bond. In this setting that link is called a peptide bond, and a chain of them is a peptide. Two amino acids make a dipeptide, three a tripeptide, and so on up to a few dozen.
Where a peptide stops and a protein starts is a convention rather than a rule. Most of the literature draws the line somewhere around fifty residues. Below it, chains tend to be flexible and are usually made by chemistry; above it, chains fold into stable three-dimensional structures and are usually made by living cells. Insulin, at fifty-one residues across two chains, sits right on the border and is called both.
The more useful contrast is with small-molecule drugs on one side and large biologics on the other. A review of impurities in peptide medicines describes the class as positioned between classic small organic molecules and larger bio-molecules such as proteins [3]. A small molecule like aspirin has a molecular weight of around 180 daltons; a typical research peptide weighs between one and five thousand; an antibody weighs about 150,000. That middle position gives peptides a particular mix of properties, discussed in section 5.
Many peptides are copies or edited versions of signalling molecules the body already makes. Hormones such as insulin, oxytocin and glucagon-like peptide 1 are peptides. So are many of the molecules immune cells use to recognise threats. Others are found in nature outside the human body, in venoms, plants and microbes, and some are designed from scratch. A 2021 perspective in Nature Reviews Drug Discovery traces these three streams, human hormones, natural products and rational design, and counts more than 80 peptide drugs that have reached the market since insulin [1].
Peptides are an increasingly important group of pharmaceuticals, positioned between classic small organic molecules and larger bio-molecules such as proteins.
2
Almost every research peptide is made by solid-phase peptide synthesis, a method Bruce Merrifield introduced in 1963 and later received a Nobel Prize for. The idea is simple. The first amino acid is anchored to a tiny resin bead. Each following amino acid is added in turn, its reactive groups masked by temporary protecting groups so that it couples only where it should. Because the growing chain is attached to a solid, excess reagent and by-products can be washed away between steps rather than separated by hand [4].
The method is reliable, but it has a known weakness that a 2013 review of synthetic methods states directly: the purity of the final product decreased with the number of coupling steps [4]. D'Hondt and colleagues catalogued what those errors look like. Deleted and inserted amino acids come from inefficient deprotection and excess reagent; side chains can be left carrying their protecting groups; oxidation and racemisation produce molecules that differ from the target by a single atom or a single mirror-image residue [3].
That is why the paperwork matters. The same review warns that peptide-related impurities possess the capability of greatly influencing initial functionality studies during early drug discovery phases, possibly resulting in erroneous conclusions [3]. A Certificate of Analysis is the record that a given lot was checked for exactly these problems. Section 7 explains how to read one.
3
Peptide science is about a century old, and three of its milestones explain most of what the field looks like today.
Working in Toronto, Frederick Banting and Charles Best, with John Macleod and James Collip, extracted insulin from pancreatic tissue in 1921. In January 1922 it was given to a fourteen-year-old patient, and a disease that had been fatal became manageable. A 2018 historical review calls the discovery an authentic breakthrough that has truly revolutionized both the therapy and the prognosis of the diabetes [5]. Insulin was the first peptide medicine, and for decades it was extracted from animal tissue rather than made.
In 1953 Vincent du Vigneaud's group completed the first laboratory synthesis of a peptide hormone, oxytocin, work recognised with the 1955 Nobel Prize in Chemistry. Ten years later Merrifield's solid-phase method turned peptide synthesis from heroic effort into routine procedure [4]. Lau and Dunn's historical overview describes how discovery then diversified beyond endogenous human peptides to structures found in other natural sources or built through medicinal chemistry [2].
Glucagon-like peptide 1 is a gut hormone that the body clears within minutes. Chemists modified it for enhanced potency and sustained action, and the resulting GLP-1 receptor agonists are, in the words of a 2019 review, successfully in clinical use for the treatment of type-2 diabetes [6]. The first was approved in the United States in 2005; semaglutide and tirzepatide followed. These are prescription medicines, manufactured under pharmaceutical rules and dispensed by pharmacies. FDA has published its concerns about unapproved versions sold outside that system [7].
Those three steps, extraction, synthesis and modification, are also the three ways peptides are still made. Lau and Dunn counted over 60 peptide drugs approved in the United States and other major markets and more than 150 in active clinical development [2]. By 2021 the count of approved peptide drugs had passed 80 [1].
4
Because peptides are the body's own signalling language, they are studied in almost every area of biology. The 2022 review in Signal Transduction and Targeted Therapy describes a wide variety of natural and modified peptides that have been obtained and studied, covering multiple therapeutic areas [8]. Four areas account for most of the literature. The descriptions below say what researchers study and what reviewers report; they are not claims about any product, and none of this is advice.
A useful habit when reading any of this literature is to ask which setting a result came from: cells in a dish, an animal model, or a registered clinical trial. The same peptide can have hundreds of papers in the first two categories and none in the third. Reviews are careful to separate them, and so should a reader.
5
When reviewers explain why interest in peptides keeps growing, they point to a consistent set of properties. These are properties of the molecular class, observed across many studies, and they come with limitations that the same reviews are careful to list.
Peptides are recognized for being highly selective and efficacious and, at the same time, relatively safe and well tolerated.
A peptide can present a large, shaped surface to its target, so it tends to bind one receptor tightly and others weakly. Reviewers describe peptides as highly selective [9], and attribute much of their appeal to that selectivity [1].
Because binding is selective and the molecules break down into amino acids, reviews report that peptides are relatively safe and well tolerated in clinical development [9]. This is a statement about the class in trials of approved candidates, not about any unapproved product.
Peptides are cleared by the same enzymes that digest dietary protein, and their breakdown products are ordinary amino acids. The flip side is a short half-life in the body, which reviewers list among the inherent drawbacks that modification strategies try to overcome [8].
A sequence can be edited one residue at a time, and solid-phase synthesis makes each variant straightforward to produce [4]. Reviews describe how swapping, adding or chemically modifying residues is used to tune potency, stability and duration of action [8].
The limitations are as well documented as the strengths. Natural peptides are usually broken down quickly, rarely survive the digestive tract, and do not easily cross cell membranes. Fosgerau and Hoffmann note that the obvious peptide targets have already been picked, and that progress now depends on routes beyond traditional peptide design, such as multifunctional peptides and peptide-drug conjugates [9]. Muttenthaler and colleagues reach a similar conclusion about the challenges that need to be addressed for peptides to reach their full potential [1].
6
A peptide's purity on the day it was analysed is a snapshot. What happens afterwards depends on chemistry and on handling. The stability literature for proteins is the nearest well-developed body of work. Manning and colleagues' widely cited 2010 review sorts instability into two families: chemical, where bonds break or form through reactions such as oxidation, deamidation and hydrolysis, and physical, where molecules aggregate, stick to surfaces or fall out of solution, and it covers stabilization in aqueous solution and the dried state separately [12]. D'Hondt and colleagues add degradation routes typical of short chains, including diketopiperazine and pyroglutamate formation [3].
A few general facts follow from that literature. They describe how research laboratories keep material stable; they are not instructions for use.
It is why a Certificate of Analysis dated two years ago tells you less than you might think about a vial today, and why the date on the certificate matters as much as the number.
7
A Certificate of Analysis, or CoA, is the laboratory report for one specific lot. It says nothing about any other lot. A useful CoA answers four questions: what is this, how much of it is the intended molecule, what else is in it, and who tested it and when.
Everything on this page describes peptides as laboratory reagents. In the United States, the phrase "research use only" comes from the rules for in-vitro products. FDA's 2013 guidance explains that an RUO label belongs on a product that is in the laboratory research phase of development and is not represented as safe or effective for any clinical purpose [13]. The label is a warning about status, not a permission. Separately, FDA maintains a public list of bulk substances nominated for compounding that may present significant safety risks, and several peptides appear on it with notes about impurities, immunogenicity and limited safety information [14]. Regulatory positions change, so read the live pages rather than any summary, including this one.
For Research Use Only. Not for use in diagnostic procedures.
Q
Both are chains of amino acids joined by peptide bonds. The difference is length and shape. Peptides are short, conventionally up to about fifty amino acids, and often flexible. Proteins are longer and fold into stable three-dimensional structures. The boundary is a convention, not a law of chemistry.
No. Approved peptide medicines such as insulin or the GLP-1 receptor agonists are prescription drugs made under pharmaceutical manufacturing rules and dispensed by pharmacies. Research-use peptides are laboratory reagents sold to researchers for in-vitro study. They are not approved for human or veterinary use and are not a substitute for a prescription product.
It is usually the HPLC area percent: the share of all detected peak area that belongs to the main peak. It describes how much of the detectable material is the intended sequence. It does not include water, salts or counter-ions, so it is not the same as the net peptide content of the powder.
Because chemical degradation reactions generally run more slowly in the dried state than in solution. Lyophilisation removes water so a peptide can be stored and shipped as a powder, then reconstituted by the laboratory under its own protocol when it is time to use it.
It means the opposite. The label marks a product that is in the laboratory research phase and has not been shown to be safe or effective for any clinical use. It is a warning about status, not a permission.
Every source in the reference list links to the publisher, PubMed Central or the issuing agency, with its PMID or DOI where one exists. The links were checked on the date shown at the top of the list.
G
One of the twenty standard building blocks of peptides and proteins. Each has the same backbone and a different side chain that gives it its character.
The amide link that joins the carboxyl group of one amino acid to the amino group of the next, forming the chain.
One amino acid once it is part of a chain. A thirty-residue peptide contains thirty amino acids. Fifty residues is the conventional upper limit of a peptide, which is where this site takes its name.
The order of residues from the N-terminus to the C-terminus. Written with one- or three-letter codes, it fully defines a peptide.
The standard method of making peptides chemically: the chain grows one amino acid at a time on a resin bead, with excess reagent washed away between steps.
High-performance liquid chromatography. Separates a mixture into components that leave a column at different times, recorded as peaks. The usual basis for a purity figure.
Measures the mass of molecules. On a CoA it confirms that the main component has the molecular weight expected from the sequence.
The share of a powder's weight that is actually peptide, after water, salts and counter-ions are accounted for. Reported separately from HPLC purity.
The oppositely charged ion paired with a peptide in its salt form, for example acetate or trifluoroacetate (TFA), left over from purification.
Freeze-drying. Removes water under vacuum so a peptide can be stored as a dry powder, where it is generally more stable than in solution.
A molecule that binds a receptor and switches it on. GLP-1 receptor agonists are prescription medicines modelled on the natural GLP-1 hormone.
A labelling status meaning a product is in the laboratory research phase and has not been shown to be safe or effective for clinical use.
R
Every link below was checked on 2026-10-08. Numbers in the text link here; the letters after each entry link back to where it was cited.
Chandrudu S, Simerska P, Toth I (2013). Chemical methods for peptide and protein production. Molecules. 18(4):4373-4388.
PMID 23584057DOI 10.3390/molecules18044373PMC6270108pmc.ncbi.nlm.nih.gov
Vecchio I, Tornali C, Bragazzi NL, Martini M (2018). The Discovery of Insulin: An Important Milestone in the History of Medicine. Front Endocrinol (Lausanne). 9:613.
PMID 30405529DOI 10.3389/fendo.2018.00613PMC6205949pmc.ncbi.nlm.nih.gov
Cited ata
Müller TD, Finan B, Bloom SR, et al. (2019). Glucagon-like peptide 1 (GLP-1). Mol Metab. 30:72-130.
PMID 31767182DOI 10.1016/j.molmet.2019.09.010PMC6812410pmc.ncbi.nlm.nih.gov
Mahlapuu M, Håkansson J, Ringstad L, Björn C (2016). Antimicrobial Peptides: An Emerging Category of Therapeutic Agents. Front Cell Infect Microbiol. 6:194.
PMID 28083516DOI 10.3389/fcimb.2016.00194PMC5186781pmc.ncbi.nlm.nih.gov